These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 35696880)

  • 1. Real-world study of relapsing-remitting multiple sclerosis patients treated with Teriflunomide in Nordic countries: Quality-Of-Life, efficacy, safety and adherence outcomes.
    Hestvik ALK; Frederiksen JL; Nielsen HH; Torkildsen Ø; Eek C; Huang-Link Y; Haghighi S; Tsai JA; Kant M
    Mult Scler Relat Disord; 2022 Jul; 63():103892. PubMed ID: 35696880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fatigue in teriflunomide-treated patients with relapsing remitting multiple sclerosis in the real-world Teri-FAST study.
    de Sèze J; Devy R; Planque E; Delabrousse-Mayoux JP; Vandhuick O; Kabir M; Gherib A
    Mult Scler Relat Disord; 2021 Jan; 47():102659. PubMed ID: 33291032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-reported outcomes in patients with relapsing forms of MS switching to teriflunomide from other disease-modifying therapies: Results from the global Phase 4 Teri-PRO study in routine clinical practice.
    Coyle PK; Khatri B; Edwards KR; Meca-Lallana JE; Cavalier S; Rufi P; Benamor M; Thangavelu K; Robinson M; Gold R;
    Mult Scler Relat Disord; 2018 Nov; 26():211-218. PubMed ID: 30273841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-reported outcomes in relapsing forms of MS: Real-world, global treatment experience with teriflunomide from the Teri-PRO study.
    Coyle PK; Khatri B; Edwards KR; Meca-Lallana JE; Cavalier S; Rufi P; Benamor M; Brette S; Robinson M; Gold R;
    Mult Scler Relat Disord; 2017 Oct; 17():107-115. PubMed ID: 29055438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Teriflunomide real-world evidence: Global differences in the phase 4 Teri-PRO study.
    Coyle PK; Khatri B; Edwards KR; Meca-Lallana JE; Cavalier S; Rufi P; Benamor M; Poole EM; Robinson M; Gold R
    Mult Scler Relat Disord; 2019 Jun; 31():157-164. PubMed ID: 31005729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world outcomes of teriflunomide in relapsing-remitting multiple sclerosis: a prospective cohort study.
    Zhang Y; Yin H; Zhang D; Xu Y; Peng B; Cui L
    J Neurol; 2022 Sep; 269(9):4808-4816. PubMed ID: 35403875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis.
    Reder AT; Arndt N; Roman C; Geremakis C; Mendoza JP; Su R; Makin C; Avila RL; Vignos MC
    Mult Scler Relat Disord; 2021 Jun; 51():102935. PubMed ID: 33882426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial.
    Chitnis T; Banwell B; Kappos L; Arnold DL; Gücüyener K; Deiva K; Skripchenko N; Cui LY; Saubadu S; Hu W; Benamor M; Le-Halpere A; Truffinet P; Tardieu M;
    Lancet Neurol; 2021 Dec; 20(12):1001-1011. PubMed ID: 34800398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serological markers exploration and real-world effectiveness and safety of teriflunomide in south Chinese patients with multiple sclerosis.
    Zhou R; Li H; Yang H; Jiang F; Cai H; Li J; Chen S; Fang L; Yin J; Zeng Q
    Mult Scler Relat Disord; 2022 Feb; 58():103446. PubMed ID: 34929454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Teriflunomide for multiple sclerosis.
    He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
    Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial.
    Kappos L; Fox RJ; Burcklen M; Freedman MS; Havrdová EK; Hennessy B; Hohlfeld R; Lublin F; Montalban X; Pozzilli C; Scherz T; D'Ambrosio D; Linscheid P; Vaclavkova A; Pirozek-Lawniczek M; Kracker H; Sprenger T
    JAMA Neurol; 2021 May; 78(5):558-567. PubMed ID: 33779698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world experience of teriflunomide in relapsing multiple sclerosis: paramagnetic rim lesions may play a role.
    Tan H; Li X; Li Y; He F; ZhangBao J; Zhou L; Yang L; Zhao C; Lu C; Dong Q; Li H; Quan C
    Front Immunol; 2024; 15():1343531. PubMed ID: 38558796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and Safety of Teriflunomide in Relapsing-Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study.
    Meca-Lallana JE; Prieto González JM; Caminero Rodríguez AB; Olascoaga Urtaza J; Alonso AM; Durán Ferreras E; Espinosa R; Dotor J; Romera M; Ares Luque A; Pérez Ruiz D; Calles C; Hernández MA; Hervás García M; Mendoza Rodríguez A; Berdei Montero Y; Téllez N; Herrera Varó N; Sotoca J; Presas-Rodríguez S; Querol Gutierrez LA; Hervás Pujol M; Batlle Nadal J; Martín Ozaeta G; Gubieras Lillo L; Martínez Yélamos S; Ramió-Torrentà L; Mallada Frechin J; Belenguer Benavides A; Gascón-Giménez F; Casanova B; Landete Pascual L; Berenguer L; Navarro L; Gómez Gutierrez M; Durán C; Rodríguez Regal A; Álvarez E; García-Estévez DA; López Real AM; Llaneza González MA; Marzo Sola ME; Sánchez-Menoyo JL; Oterino A; Villaverde González R; Castillo-Triviño T; Álvarez de Arcaya A; Llarena C
    Neurol Ther; 2023 Dec; 12(6):2177-2193. PubMed ID: 37861931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and safety of switching to teriflunomide in older patients with relapsing multiple sclerosis: A real-world retrospective multicenter analysis.
    Berkovich R; Negroski D; Wynn D; Sellers D; Bzdek KG; Lublin AL; Rawlings AM; Quach C; Wells DP; Dumlao M; Bora A; Ranno AE; Luo KL; Chavin J; Hua LH; Becker D
    Mult Scler Relat Disord; 2023 Feb; 70():104472. PubMed ID: 36566698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An updated review of teriflunomide's use in multiple sclerosis.
    Miller AE
    Neurodegener Dis Manag; 2021 Oct; 11(5):387-409. PubMed ID: 34486382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis Registry.
    Papp V; Buron MD; Siersma V; Rasmussen PV; Illes Z; Kant M; Hilt C; Mezei Z; Roshanisefat H; Sejbæk T; Weglewski A; van Wingerden J; Geertsen SS; Bramow S; Sellebjerg F; Magyari M
    PLoS One; 2021; 16(5):e0250820. PubMed ID: 34003862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-World Assessment of Quality of Life in Patients with Relapsing Remitting Multiple Sclerosis Treated with Teriflunomide for Two Years: Patient-Reported Outcomes from the AURELIO Study in Greece.
    Dardiotis E; Perpati G; Borsos M; Nikolaidis I; Tzanetakos D; Deretzi G; Koutlas E; Kilidireas C; Mitsikostas DD; Hadjigeorgiou G; Grigoriadis N;
    Neurol Ther; 2022 Sep; 11(3):1375-1390. PubMed ID: 35829919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real world experience with teriflunomide in multiple sclerosis: the TER-Italy study.
    Bucello S; Annovazzi P; Ragonese P; Altieri M; Barcella V; Bergamaschi R; Bianchi A; Borriello G; Buscarinu MC; Callari G; Capobianco M; Capone F; Cavalla P; Cavarretta R; Cortese A; De Luca G; Di Filippo M; Dattola V; Fantozzi R; Ferraro E; Filippi MM; Gasperini C; Grimaldi LME; Landi D; Re ML; Mallucci G; Manganotti P; Marfia GA; Mirabella M; Perini P; Pisa M; Realmuto S; Russo M; Tomassini V; Torri-Clerici VLA; Zaffaroni M; Zuliani C; Zywicki S; Filippi M; Prosperini L
    J Neurol; 2021 Aug; 268(8):2922-2932. PubMed ID: 33616742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Ponesimod Compared with Teriflunomide in Female Patients with Relapsing Multiple Sclerosis: Findings from the Pivotal OPTIMUM Study.
    Jones RR; Turkoz I; Ait-Tihyaty M; DiBernardo A; Houtchens MK; Havrdová EK
    J Womens Health (Larchmt); 2024 Apr; 33(4):480-490. PubMed ID: 38301149
    [No Abstract]   [Full Text] [Related]  

  • 20. Long-term safety and efficacy of teriflunomide in patients with relapsing multiple sclerosis: Results from the TOWER extension study.
    Miller AE; Olsson TP; Wolinsky JS; Comi G; Kappos L; Hu X; Xu X; Lublin AL; Truffinet P; Chavin J; Delhay JL; Benamor M; Purvis A; Freedman MS;
    Mult Scler Relat Disord; 2020 Nov; 46():102438. PubMed ID: 32911306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.